- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Bhuvana Sagar, MD, Discusses Maintaining Cost Efficiency While Using Biosimilars
Bhuvana Sagar, MD, the national medical executive at Cigna Health Care, discusses the importance of maintaining cost efficiency when juggling multiple biosimilars for 1 originator in the practice setting.
Bhuvana Sagar, MD, the national medical executive at Cigna Health Care, discusses how Cigna has balanced using multiple biosimilars for 1 originator while also maintaining cost efficiency.
As more biosimilars enter the market, competition for market share overall helps to decrease the total cost of care; however, too many choices for a reference drug can create cost inefficiencies.
Sagar explained that in order to manage this, Cigna met with its large providers, including community oncologists and others, to gain feedback on current practice issues.
Knowing which drugs are on the market and which ones are gaining the most market share helps to lower the unit cost for prescriptions and ensures cost-efficiency for both patients and employers. Sagar said that working with providers is how Cigna makes sure that providers can accommodate their policies as easily as possible.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
